Cargando…
Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital
BACKGROUND: We previously reported an increase in meropenem prescriptions for Pseudomonas aeruginosa infections in our hospital after the implementation of the 10th version of the EUCAST breakpoints table for P. aeruginosa in January 2020. As a consequence, antibiotic susceptibility testing results...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805013/ https://www.ncbi.nlm.nih.gov/pubmed/36585736 http://dx.doi.org/10.1186/s13756-022-01203-x |
_version_ | 1784862245794086912 |
---|---|
author | Munting, Aline Damas, José Viala, Benjamin Prod’hom, Guy Guery, Benoit Senn, Laurence |
author_facet | Munting, Aline Damas, José Viala, Benjamin Prod’hom, Guy Guery, Benoit Senn, Laurence |
author_sort | Munting, Aline |
collection | PubMed |
description | BACKGROUND: We previously reported an increase in meropenem prescriptions for Pseudomonas aeruginosa infections in our hospital after the implementation of the 10th version of the EUCAST breakpoints table for P. aeruginosa in January 2020. As a consequence, antibiotic susceptibility testing results were adapted by masking meropenem for P. aeruginosa isolates susceptible to either ceftazidime, cefepime or piperacillin-tazobactam. We aimed to assess the changes in meropenem prescriptions after the implementation of the selective reporting. METHODS: In this retrospective single-centre observational study, we analysed antimicrobial therapies prescribed for P. aeruginosa infections after the susceptibility testing results have been made available over three periods: “before EUCAST update”, “after EUCAST update without selective reporting” and “after EUCAST update with selective reporting”, at Lausanne University Hospital, Switzerland. We collected epidemiological, microbiological and clinical data. The primary outcome was the prescription of meropenem to treat P. aeruginosa infections after the release of susceptibility testing results. Secondary outcomes were the use of increased dosage of non-meropenem anti-pseudomonal drugs, and IDs’ consultations rates after the release of susceptibility testing results. RESULTS: Among the 457 patients included, 65 (14.2%) received meropenem: 5/148 (3.4%) before EUCAST update, 51/202 (25.3%) after EUCAST update without selective reporting, and 9/107 (8.4%) after EUCAST update with selective reporting. Supervision and counselling from IDs as well as the use of increased dosages of non-carbapenem antibiotics increased in both periods after EUCAST update, compared to the first period, respectively: 40.5% (60/148) versus 61.4% (124/202) versus 51.4% (55/107) (P < 0.001), and 57.9% (84/148) versus 91.1% (183/202) versus 90.7% (97/107) (P < 0.001). CONCLUSIONS: Selective reporting of antibiotic susceptibility testing results might decrease unnecessary meropenem prescriptions for the treatment of P. aeruginosa infections and could be part of multimodal antibiotic stewardship interventions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13756-022-01203-x. |
format | Online Article Text |
id | pubmed-9805013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98050132023-01-01 Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital Munting, Aline Damas, José Viala, Benjamin Prod’hom, Guy Guery, Benoit Senn, Laurence Antimicrob Resist Infect Control Research BACKGROUND: We previously reported an increase in meropenem prescriptions for Pseudomonas aeruginosa infections in our hospital after the implementation of the 10th version of the EUCAST breakpoints table for P. aeruginosa in January 2020. As a consequence, antibiotic susceptibility testing results were adapted by masking meropenem for P. aeruginosa isolates susceptible to either ceftazidime, cefepime or piperacillin-tazobactam. We aimed to assess the changes in meropenem prescriptions after the implementation of the selective reporting. METHODS: In this retrospective single-centre observational study, we analysed antimicrobial therapies prescribed for P. aeruginosa infections after the susceptibility testing results have been made available over three periods: “before EUCAST update”, “after EUCAST update without selective reporting” and “after EUCAST update with selective reporting”, at Lausanne University Hospital, Switzerland. We collected epidemiological, microbiological and clinical data. The primary outcome was the prescription of meropenem to treat P. aeruginosa infections after the release of susceptibility testing results. Secondary outcomes were the use of increased dosage of non-meropenem anti-pseudomonal drugs, and IDs’ consultations rates after the release of susceptibility testing results. RESULTS: Among the 457 patients included, 65 (14.2%) received meropenem: 5/148 (3.4%) before EUCAST update, 51/202 (25.3%) after EUCAST update without selective reporting, and 9/107 (8.4%) after EUCAST update with selective reporting. Supervision and counselling from IDs as well as the use of increased dosages of non-carbapenem antibiotics increased in both periods after EUCAST update, compared to the first period, respectively: 40.5% (60/148) versus 61.4% (124/202) versus 51.4% (55/107) (P < 0.001), and 57.9% (84/148) versus 91.1% (183/202) versus 90.7% (97/107) (P < 0.001). CONCLUSIONS: Selective reporting of antibiotic susceptibility testing results might decrease unnecessary meropenem prescriptions for the treatment of P. aeruginosa infections and could be part of multimodal antibiotic stewardship interventions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13756-022-01203-x. BioMed Central 2022-12-30 /pmc/articles/PMC9805013/ /pubmed/36585736 http://dx.doi.org/10.1186/s13756-022-01203-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Munting, Aline Damas, José Viala, Benjamin Prod’hom, Guy Guery, Benoit Senn, Laurence Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital |
title | Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital |
title_full | Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital |
title_fullStr | Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital |
title_full_unstemmed | Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital |
title_short | Impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of Pseudomonas aeruginosa infections after 2020 EUCAST criteria update: an observational study in a university hospital |
title_sort | impact of selective reporting of antibiotic susceptibility testing results on meropenem prescriptions for the treatment of pseudomonas aeruginosa infections after 2020 eucast criteria update: an observational study in a university hospital |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805013/ https://www.ncbi.nlm.nih.gov/pubmed/36585736 http://dx.doi.org/10.1186/s13756-022-01203-x |
work_keys_str_mv | AT muntingaline impactofselectivereportingofantibioticsusceptibilitytestingresultsonmeropenemprescriptionsforthetreatmentofpseudomonasaeruginosainfectionsafter2020eucastcriteriaupdateanobservationalstudyinauniversityhospital AT damasjose impactofselectivereportingofantibioticsusceptibilitytestingresultsonmeropenemprescriptionsforthetreatmentofpseudomonasaeruginosainfectionsafter2020eucastcriteriaupdateanobservationalstudyinauniversityhospital AT vialabenjamin impactofselectivereportingofantibioticsusceptibilitytestingresultsonmeropenemprescriptionsforthetreatmentofpseudomonasaeruginosainfectionsafter2020eucastcriteriaupdateanobservationalstudyinauniversityhospital AT prodhomguy impactofselectivereportingofantibioticsusceptibilitytestingresultsonmeropenemprescriptionsforthetreatmentofpseudomonasaeruginosainfectionsafter2020eucastcriteriaupdateanobservationalstudyinauniversityhospital AT guerybenoit impactofselectivereportingofantibioticsusceptibilitytestingresultsonmeropenemprescriptionsforthetreatmentofpseudomonasaeruginosainfectionsafter2020eucastcriteriaupdateanobservationalstudyinauniversityhospital AT sennlaurence impactofselectivereportingofantibioticsusceptibilitytestingresultsonmeropenemprescriptionsforthetreatmentofpseudomonasaeruginosainfectionsafter2020eucastcriteriaupdateanobservationalstudyinauniversityhospital |